Gilead Sciences

Gilead Sciences Announces Completion of Acquisition of CymaBay

Retrieved on: 
Friday, March 22, 2024
Health, Hospitals, General Health, Research, Science, Pharmaceutical, Biotechnology, EPS, Patient, Gilead Sciences, Acquisition, Primary biliary cholangitis, PBC, Therapy, Safety, Itch, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately $4.3 billion in total equity value.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately $4.3 billion in total equity value.
  • “The acquisition of CymaBay brings us a potential best in disease therapy that could transform the treatment landscape for people with primary biliary cholangitis,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences.
  • “I want to thank the CymaBay team for their efforts and commitment to addressing this high unmet need.
  • Pursuant to the merger agreement, Gilead and Purchaser commenced a tender offer on February 23, 2024, to acquire all outstanding shares of CymaBay at a price of $32.50 per share.

Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress

Retrieved on: 
Tuesday, March 19, 2024
Research, FDA, Clinical Trials, Cardiology, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Overweight, SMN, Conference, Obesity, Keystone, MDA, Gilead Sciences, SAPPHIRE, SMA, Manuscript, Myostatin, Rock, Muscular dystrophy, Muscular Dystrophy Association, Trial of the century, Efficacy, Clinical trial, Therapy, Literature, Lunch, Pharmaceutical industry

“In 2023, Scholar Rock made significant progress across our industry-leading antimyostatin pipeline, and we are poised for a transformational year ahead.

Key Points: 
  • “In 2023, Scholar Rock made significant progress across our industry-leading antimyostatin pipeline, and we are poised for a transformational year ahead.
  • Scholar Rock remains on track to report topline data from the Phase 3 trial in the fourth quarter of 2024.
  • Scholar Rock also presented a literature review that describes the ongoing burden and significant unmet needs in SMA despite advancements in treatment.
  • Dr. Qatanani joined Scholar Rock in 2021 and has been leading all research functions since 2022 and driving Scholar Rock’s early-stage pipeline, including SRK-439.

Diversity Research Institute to Honor Diversity First Top Companies for Diversity and their CEOs at the 20th Annual National Diversity & Leadership Conference in Dallas, TX

Retrieved on: 
Wednesday, March 13, 2024
Professional Services, Business, Human Resources, DEI (Diversity, Equity and Inclusion), Xerox, Kraft Heinz, Microsoft, Bath & Body Works, Hewlett-Packard, Rocket Mortgage, Intel, EBay, Kimberly-Clark, Bath, Conference, PG&E, The Walt Disney Company, Organization, TIAA, AES Corporation, Procter, Coca-Cola, Procter & Gamble, Uber, Health, Gilead Sciences, Edison International, Bank, Diversity, Bristol Myers Squibb, Shantanu Narayen, Avis Budget Group, Science, Rite Aid, CVS Health, Ulta Beauty, Verizon Communications, Conagra Brands, UPS, Science Applications International Corporation, BNY Mellon, DRI, Vertex Pharmaceuticals, Otis Worldwide, Omnicom Group, CDW, DEI

The companies to be honored were selected from the U.S. Fortune 500 Governance Report (2023) published by Diversity First and DRI last year.

Key Points: 
  • The companies to be honored were selected from the U.S. Fortune 500 Governance Report (2023) published by Diversity First and DRI last year.
  • The report evaluates the executive and board demographics of U.S. Fortune 500 companies.
  • It assesses racial/ethnic and gender demographics of each company according to 2019 U.S. Census Data, providing each company with a score and a ranking.
  • The DRI, in affiliation with Diversity First, lists the companies with the highest scores as Diversity First Top 50 Companies.

Protesters Keep Heat on Greedy Gilead over Price Gouging

Retrieved on: 
Wednesday, March 13, 2024
Men, General Health, Pharmaceutical, Consumer, State, Local, Infectious Diseases, Public Policy, Health Insurance, Women, AIDS, Health, Government, HIV/AIDS, Conference, AIDS Healthcare Foundation, HIV, Gilead Sciences, AHF, Multimedia, Pharmacy, Pharmaceutical industry

HIV/AIDS advocates from AIDS Healthcare Foundation (AHF) will continue their campaign of protests targeting Gilead Sciences over the company’s ongoing efforts to rack up exorbitant profits while restricting access to its lifesaving medications.

Key Points: 
  • HIV/AIDS advocates from AIDS Healthcare Foundation (AHF) will continue their campaign of protests targeting Gilead Sciences over the company’s ongoing efforts to rack up exorbitant profits while restricting access to its lifesaving medications.
  • Protesters will gather Wednesday in front of the Loews Miami Beach Hotel where executives from Gilead will be presenting at the Barclays Annual Global Health Conference.
  • View the full release here: https://www.businesswire.com/news/home/20240312694416/en/
    The group hosted a similar protest rally targeting Gilead at the Fontainebleau Miami Beach Hotel Tuesday while company executives presented during the Leerink Partners Biopharma Conference.
  • HIV/AIDS activists are also specifically targeting Gilead CEO Daniel O’Day over his February appointment as board chair for PhRMA (Pharmaceutical Research and Manufacturers of America), the cutthroat trade group representing companies in the pharmaceutical industry in the United States.

AHF Keeps Pressure on ‘Greedy Gilead’ Over Price Gouging

Retrieved on: 
Monday, March 11, 2024
Pharmaceutical, Philanthropy, Infectious Diseases, Healthcare Reform, Social Activism, Public Policy, Advocacy Group Opinion, Foundation, Communications, AIDS, Health, Government, HIV/AIDS, Conference, AIDS Healthcare Foundation, HIV, Gilead Sciences, City, AHF, Pharmacy, Pharmaceutical industry

AIDS Healthcare Foundation (AHF) advocates will rally at the Fontainebleau Miami Beach Hotel Tuesday to protest Gilead Sciences ’ ongoing efforts to rack up exorbitant profits while restricting access to lifesaving medications.

Key Points: 
  • AIDS Healthcare Foundation (AHF) advocates will rally at the Fontainebleau Miami Beach Hotel Tuesday to protest Gilead Sciences ’ ongoing efforts to rack up exorbitant profits while restricting access to lifesaving medications.
  • AHF’s sustained protests against the drug maker continue as Gilead faces legal action over its keeping safer HIV medications off the market to maximize profits.
  • “It is so sadly apropos that Gilead CEO Daniel O’Day — the poster child for PhRMA greed — also now sits atop PhRMA, the undisputed fortress of greed,” said Michael Weinstein, AHF president and cofounder.
  • Since 2021, AHF has been taking on Gilead and CEO Daniel O’Day, holding more than two dozen protests in multiple cities, including Washington, DC, Miami, Boston, and Foster City, CA at Gilead’s corporate headquarters.

Scispot Welcomes Pharma Leader Dr. Sarah Warren to Advisory Board

Retrieved on: 
Thursday, March 21, 2024
Organization, Advisory board, Growth, Gilead Sciences, Evaluation, Research, Business development, AI, Cell

KITCHENER, Ontario, March 21, 2024 /PRNewswire-PRWeb/ -- Scispot, a leading life science tech stack provider, proudly welcomes Dr. Sarah Warren as its latest Scientific Advisor. Dr. Warren, who serves as the Senior Director of Business Development - Cell Therapy Search and Evaluation at Gilead Sciences, brings a wealth of expertise to the Scispot team. Her appointment signals a significant step forward for Scispot as the company embarks on a new chapter, expanding its innovative offerings to the larger pharmaceutical companies. Leveraging its expertise, Scispot is set to revolutionize R&D processes for larger organizations by enhancing lab interoperability and preparing data for AI applications, facilitating faster and more efficient development of life-saving drugs.

Key Points: 
  • KITCHENER, Ontario, March 21, 2024 /PRNewswire-PRWeb/ -- Scispot , a leading life science tech stack provider, proudly welcomes Dr. Sarah Warren as its latest Scientific Advisor.
  • Dr. Warren, who serves as the Senior Director of Business Development - Cell Therapy Search and Evaluation at Gilead Sciences, brings a wealth of expertise to the Scispot team.
  • The inclusion of Dr. Warren on Scispot's Advisory Board signifies a crucial step towards integrating advanced AI and data science in biotech R&D, reinforcing the company's position as a leader in the field.
  • Looking ahead, Scispot plans to welcome more industry leaders to the Advisory Board, strengthening its mission to blend biology with technology.

Hyku Biosciences, a Covalent Precision Medicine Company, Announces CEO Transition for its Next Phase of Growth

Retrieved on: 
Monday, March 11, 2024
Gilead Sciences, Chemistry, Mantra, Sale, IPO, Doctor of Philosophy, University, Therapy, Business, Organization, Novartis, Bachelor of Science, Science, Biogen, Management

LEXINGTON, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Hyku Biosciences, Inc. (Hyku), a covalent precision medicine company, today announced the appointment of Kleem Chaudhary, Ph.D. as President and Chief Executive Officer, succeeding co-founder and acting CEO Milind Deshpande, Ph.D. who will now serve as an advisor to the company. Dr Chaudhary will also serve as a member of the Board of Directors of Hyku.

Key Points: 
  • Dr Chaudhary will also serve as a member of the Board of Directors of Hyku.
  • Most recently, he was Chief Operating and Business Officer at Redona Therapeutics.
  • Dr. Chaudhary holds a Ph.D. in chemistry from the University of North Carolina at Chapel Hill and a B.Sc.
  • “We are excited to have Kleem join Hyku and I look forward to working with him to advance the exciting science at Hyku.”

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – STER), Societal CDMO Check Corp. (Nasdaq – SCTL)

Retrieved on: 
Thursday, February 29, 2024
IGT, Gilead Sciences, Brodsky, Society, First, Sterling, GILD, Silver Strand (San Diego), Therapy, International Game Technology, Everi Holdings, Security (finance)

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the agreement, CymBay will be acquired by Gilead Sciences, Inc. (Nasdaq - GILD).
  • Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.
  • Under the terms of the agreement, Societal CDMO will be acquired by CoreRx, Inc. (“CoreRx”) for $1.10 per share in cash.

Abingworth Announces a Strategic Development Financing Agreement with Gilead Sciences; Establishes Joint Steering Committee between Launch Therapeutics and Gilead Sciences

Retrieved on: 
Thursday, February 29, 2024
Lung cancer, Gilead Sciences, Pharmaceutical industry

London, UK and New York, USA, February 29, 2024 - Abingworth, a leading international life sciences investment group, part of global investment firm Carlyle (NASDAQ: CG), today announced a strategic development financing agreement with Gilead Sciences.

Key Points: 
  • London, UK and New York, USA, February 29, 2024 - Abingworth, a leading international life sciences investment group, part of global investment firm Carlyle (NASDAQ: CG), today announced a strategic development financing agreement with Gilead Sciences.
  • The financing agreement will provide up to $210 million in funding to support select clinical studies of Trodelvy® (sacituzumab govitecan-hziy), within non-small cell lung cancer.
  • As part of the agreement, Launch Therapeutics, a clinical development company backed by Abingworth and Carlyle, and Gilead have entered into a clinical collaboration agreement that establishes a Joint Steering Committee throughout development.
  • Gilead retains full rights to Trodelvy and, if development is successful, Abingworth would receive a fixed payment upon regulatory approval of a pre-defined label expansion, as well as royalty payments based on U.S. Trodelvy net sales within the specific tumor type.

CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, February 28, 2024
Alkaline phosphatase, Acquisition, Liver, Child, Therapy, EMA, Ursodeoxycholic acid, New Drug Application, Gilead Sciences, Education, IDEAL, FDA, Science, Quality of life, Food, Marketing, U.S. FDA, Breakthrough, ALP, Hospital, PBC, Phase 3, Cirrhosis, Hepatology, Seladelpar, Safety, ULN, European Medicines Agency, Numerical, Patient, MHRA, UDCA, Itch, NDA, NRS, Pharmaceutical industry

NEWARK, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the year and fourth quarter ended December 31, 2023.

Key Points: 
  • NEWARK, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the year and fourth quarter ended December 31, 2023.
  • “2023 was a seminal year for CymaBay with critical achievements in the development of our investigational therapeutic, seladelpar.
  • Net loss for the year ended December 31, 2023 and 2022 was $105.4 million and $106.0 million, or ($0.99) and ($1.21) per share, respectively.
  • Net loss for the three months ended December 31, 2023 was higher than the three months ended December 31, 2022 primarily due to higher operating expenses.